UCL researchers have invented a new test to identify the earliest genetic changes of prostate cancer in blood - Prostatic adenocarcinoma with perineural invasion. Credit: Nephron on Wikimedia Commons (CC BY-SA 3.0)
UCL researchers have invented a new test to identify the earliest genetic changes of prostate cancer in blood - Prostatic adenocarcinoma with perineural invasion. Credit: Nephron on Wikimedia Commons (CC BY-SA 3. Giving the drug abiraterone alongside standard hormone therapy helps men with high-risk prostate cancer that has not spread elsewhere in the body to live longer, according to preliminary results of a UCL-led trial. This result from the STAMPEDE trial, based at the MRC Clinical Trials Unit at UCL and funded by Cancer Research UK and MRC, was presented today at the European Society for Medical Oncology (ESMO) Congress. Lead researcher Professor Gert Attard (UCL Cancer Institute) presented an analysis of the impact of abiraterone, when used either with or without another drug, enzalutamide, when added to standard hormone therapy for men with prostate cancer where conventional imaging shows it has not spread elsewhere in the body. 988 men were randomised to receive standard of care (hormone therapy with or without radiotherapy). They were compared to 986 men who were randomised to receive abiraterone, plus standard of care (hormone therapy with or without radiotherapy). Of those in the abiraterone group, 527 men also received enzalutamide.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
